Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 6, 2012, Pages 383-390

  Zeitlinger, Markus ^a   Rusca, Antonio ^b   Oraha, Alhan Z ^c   Gugliotta, Barbara ^d   Müller, Markus ^a   Ducharme, Murray P ^c,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Cross Research SA   (Switzerland)

^c Cetero Research   (United States)

^d Institut Biochimique SA   (Switzerland)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Diclofenac; HP CD; Linearity; NSAID; Pharmacokinetics; Relative bioavailability

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; DICLOFENAC;

ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DICLOFENAC; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE;

EID: 84861835844     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201600     Document Type: Article

References (11)

1. Gan T. J. Diclofenac: An Update on its Mechanism of Action and Safety Profile. Curr Med Res Opin. 2010; 25: 1715-1731. doi:10.1185/03007995.2010. 486301
2. Zippel H, Wagenitz A. A multicentre, randomised, double-blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain. Clin Drug Investig. 2007; 27: 533-543. doi:10.2165/00044011-2007270 80-00002 PubMed
3. McCormack PL, Scott LJ. Diclofenac sodium injection (Dyloject): in postoperative pain. Drugs. 2008; 68: 123-130. doi:10.2165/00003495-200 868010-00008 PubMed
4. Novartis Pharmaceuticals UK. Ltd. Voltarol ampoules: summary of product characteristics. Electronic Medicines Compendium (eMC). Available from http://www.medicines.org.uk/EMC/medicine/1339/SPC/Voltarol+Ampoules/. Accessed December 4, 2010.
5. Therabel Pharma UK. Limited. Dyloject solution: summary of product characteristics. The Electronic Medicines Compendium (eMC). Available from http://www.medicines.org.uk/EMC/medicine/20668/SPC/ Dyloject+75+mg+2+ml+solution+for+injection/. Accessed December 4, 2010.
6. Ojha A, Shep D, Nivsarkar M, Patel S, Jaiswal V, Padh H. Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use. Expert Opin Pharmacother. 2009; 10: 517-522. doi:10.151 7/1465 656090 27 320 66 PubMed
7. Prettyman J. Subcutaneous or intramuscular? Confronting a parenteral administration dilemma. Medsurg Nurs. 2005; 14: 93-98. PubMed
8. Shep D, Ojha A, Patel S, Nivsarkar M, Jaiswal V, Padh H. Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers. J Pain Res. 2010; 3: 235-240. PubMed
9. Small SP. Preventing sciatic nerve injury from intramuscular injections: literature review. J Adv Nurs. 2004; 47: 287-296. doi:10.1111/j.1365-2648.2004. 03092.x PubMed (Pubitemid 39090699)
10. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1982: 494.
11. Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1988; 35: 244-285. doi:10.2165/00003495-198835030-00004 PubMedd